دورية أكاديمية
أعرض في EDS

Antithrombotic therapy following transcatheter aortic valve intervention.

التفاصيل البيبلوغرافية
العنوان: Antithrombotic therapy following transcatheter aortic valve intervention.
المؤلفون: Sharma H; Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, UK; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK., Afzal S; Heartcenter Trier, Krankenhaus der Barmherzigen Brüder, Trier, Germany., Leick J; Heartcenter Trier, Krankenhaus der Barmherzigen Brüder, Trier, Germany., Werner N; Heartcenter Trier, Krankenhaus der Barmherzigen Brüder, Trier, Germany., Doshi SN; Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, UK; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK., Nadir MA; Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, UK; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK. Electronic address: adnan.nadir@uhb.nhs.uk.
المصدر: Pharmacology & therapeutics [Pharmacol Ther] 2023 Oct; Vol. 250, pp. 108509. Date of Electronic Publication: 2023 Aug 11.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7905840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-016X (Electronic) Linking ISSN: 01637258 NLM ISO Abbreviation: Pharmacol Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford, Elmsford, N. Y., Pergamon Press.
مواضيع طبية MeSH: Transcatheter Aortic Valve Replacement*/adverse effects , Transcatheter Aortic Valve Replacement*/methods , Aortic Valve Stenosis*/drug therapy , Aortic Valve Stenosis*/surgery, Humans ; Aortic Valve/surgery ; Fibrinolytic Agents/therapeutic use ; Treatment Outcome ; Risk Factors
مستخلص: Transcatheter aortic valve replacement (TAVR) is increasingly being performed to treat symptomatic patients with aortic stenosis and annual procedure volume has overtaken surgical aortic valve replacement in the United States. However, current international guidelines were written prior to the publication of several important recent studies. Furthermore, European and American guidelines differ in their recommendations of antithrombotic therapy following TAVR. Consequently, there is a need to examine the literature to provide clinicians guidance on the optimum antithrombotic strategy, particularly as different patient populations exist. In this review, we examine the data for antiplatelet and anticoagulation therapy post-TAVR.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2023. Published by Elsevier Inc.)
فهرسة مساهمة: Keywords: Anticoagulation; Antiplatelets; Antithrombotics; Transcatheter aortic valve replacement
المشرفين على المادة: 0 (Fibrinolytic Agents)
تواريخ الأحداث: Date Created: 20230812 Date Completed: 20231002 Latest Revision: 20231011
رمز التحديث: 20231012
DOI: 10.1016/j.pharmthera.2023.108509
PMID: 37572882
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-016X
DOI:10.1016/j.pharmthera.2023.108509